OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development

SAN DIEGO, Oct. 18, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will be holding its inaugural Investor & Analyst Day on November 17^th in San Diego, where the Company will share updates on its clinical development plan for melanoma, advancement on its intratumoral immunotherapy pipeline of DNA-based product candidates, and next generation research and device development. The event will be webcast live via video stream beginning at 9:00 AM Pacific Time, and will be available through the Events section under the Investors tab of OncoSec's website at www.oncosec.com.  The webcast will also be available for replay on the Company website.

The approximately two-hour agenda for the Investor & Analyst Day is intended to provide a comprehensive overview of OncoSec. Presentations will be made by Key Opinion Leaders in the Immuno-Oncology field, collaborators, and OncoSec's management team. The presentations will focus on the following areas:

• ImmunoPulse^® IL-12 melanoma clinical development plan and overview of the next registration-directed study (including a recap of clinical data);
• New research and pre-clinical data from OncoSec's broader ImmunoPulse^® pipeline;
• Pre-clinical and regulatory objectives to initiate a Phase I clinical study of a new combination molecule candidate; and a,
• Special presentation and announcement regarding the Company's new device(s) including new research data.

The Company will distribute additional details in subsequent communications. 

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer.  ImmunoPulse^® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse^®IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse^®IL-12, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse^® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse^® platform. For more information, please visit www.oncosec.com.

CONTACT:
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
855-662-6732
[email protected]

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com